Transplantation of allogeneic pancreatic islets is an effective approach to treat type 1 diabetes. To bypass the need for systemic administration of immunosuppression drugs following transplantation, approaches to genetically modify allogeneic islets to express anti-inflammatory, immunosuppressive, or antiapoptotic proteins prior to transplantation are being developed. Adeno-associated viral (AAV) based vectors have been used for gene transfer to islets, but the efficiency of functional transduction is low. Recently, doublestranded (ds) or double-copy (dc) based AAV vectors have been developed that allow for more rapid and efficient AAVmediated transgene expression following transduction. Here we demonstrate that intact human and murine islets can be transduced with dsAAV2-eGFP efficiently compared to single-stranded AAV2-eGFP. Furthermore, our results demonstrate that murine islets transduced with dsAAV2-eGFP have normal islet glucose responsiveness, viability, and islet insulin content. Transplantation of the dsAAV2-eGFP transduced islet restored normal glycemia in diabetic mice without eliciting an immune response. Significant dsAAV2-mediated eGFP expression was observed in the islet grafts for at least 6 months post-transplant. Finally, we demonstrated that dsAAV serotypes 2, 6, and 8 infect human islets efficiently. Taken together, these results suggest that dsAAV based vectors are highly appropriate for gene transfer to islets to facilitate transplantation.
Introduction
Type 1 diabetes is an autoimmune disease, also known as insulin dependent diabetes mellitus (IDDM), in which insulin producing b-cells of the pancreatic islets of Langerhans are selectively destroyed by the immune system. 1 Multiple effectors of the immune system, including cytotoxic T cells, macrophages, and antibodies, mediate a selective destruction of the b-cells resident within the islets. [2] [3] [4] [5] Transplantation of allogeneic pancreatic islets is an attractive alternative treatment for patients with type-1 diabetes, 6, 7 but the allogeneic, autoimmune, and alloimmune response to the allogeneic donor islets severely limits graft survival. Development of potent immunosuppressive drugs has contributed to the improvement of islet graft survival; however, these conventional drugs are associated with adverse effects such as an increase in infection and development of malignancy due to their nonspecific suppression of host immune responses. 8, 9 Additionally, some of the immunosuppressive agents directly limit the function of b-cells. 10 Given the limitations associated with conventional immunosuppressive drug regiments, we and others have examined the ability to modulate the allo and autoimmune responses to islet allografts by direct gene transfer. Genetic modification of the islets to express immunosuppressive or anti-inflammatory agents, in theory, can locally block allograft rejection, allowing for long-term survival of the transplanted cells. For example, transfer of genes encoding immunomodulatory and cell protective molecules such as CTLA4-Ig, sCD40-Ig, IL-4, IL-10, hemoxygenase, MnSOD, and Bcl-2 to islets has resulted in prolonged survival and/or function of the transplant. [11] [12] [13] [14] [15] [16] However, the rate-limiting step for successful clinical application of gene transfer to islets to facilitate transplantation is the efficiency of gene delivery. Adenoviral vectors have been used extensively for infection of both human and rodent islets, resulting in gene transfer to greater than 50% of the b-cells within the intact islet without interfering with b-cell function. 17, 18 The disadvantage of adenoviral vectors is that gene expression is transient, due in part to the inherent immunogenicity of first generation, E1 adenoviral vectors. Whether the immunogenicity of the adenoviral vectors can be overcome by using gutted adenoviral vectors still remains to be determined.
Human immunodeficiency virus (HIV) based lentiviral vectors have also been used to infect human islets, resulting in efficient stable modification of b-cells. 11, 19, 20 Previous results suggest that equine infectious anemia virus (EIAV) and feline immunodeficiency virus (FIV) based vectors also can infect human islets, but at a lower efficiency than HIV based vectors. 21 However, currently, there are issues regarding production and safety of lentiviral vectors that have slowed the development of lentiviral based clinical gene therapy trials. 22 Adeno-associated virus (AAV) based vectors can infect both dividing and nondividing cells with minimal toxicity, resulting in long-term efficient transgene expression in animal models with limited immunogenicity. 23 The traditional, single-stranded AAV vectors (ssAAV) transduce both human and murine islets, but require high MOI and adenovirus coinfection to enhance transgene expression. [23] [24] [25] AAV packages and delivers a single-stranded genome, which is transcriptionally inactive until it is converted into double-stranded (ds) template. The slow onset of transgene expression after delivery of ssAAV is partly due to either the requirement for de novo synthesis of the second strand of DNA or the annealing of the plus and minus strand of the two separate coinfected viral particles. [26] [27] [28] The delayed expression of therapeutic transgene limits the utility of this approach in situations where immediate intervention is required. Another limitation of AAV by at least certain serotypes is the poor transduction efficiency of human islets. In an attempt to improve AAV transduction, AAV vectors that can package a self-complementary double-stranded, hairpin-like genome have been developed, thus circumventing the rate-limiting step of conversion of ss to dsDNA. AAV vectors exclusively packaging dsDNA genome were generated by mutating one of the AAV inverted terminal repeats (ITR). In the present study, we show that a dsAAV2-eGFP vector can infect both human and murine intact islets efficiently in culture. Moreover, GFP expression in the AAV-transduced islets persists for at least 6 months following transplant into syngeneic recipients without affecting the ability of the islets to respond to glucose. Finally, we demonstrate that AAV serotypes 2, 8 and, in particular, 6 infect human islets more efficiently than serotypes 1, 5, and 7. These results suggest that dsAAV-based vectors are potentially clinically useful for stable genetic modification of human islets to facilitate transplantation.
Results
dsAAV vectors transduce human and mouse pancreatic islets at greater efficiency compared to single-stranded AAV vectors. To examine whether dsAAV2-eGFP can transduce islets more efficiently than ssAAV2-eGFP vectors, we compared AAV2 based ss and ds strand vectors in human and murine islets and in the rat INS-1 b cell-line. As shown in Figure 1 , the dsAAV vector transduced both human ( Figure 1c ) and murine ( Figure  1f ) islets more efficiently compared to ssAAV ( Figure  1b ,e) when examined 1 week post-transduction at a dose of 10 000 vg (viral genomes) per islet cell. The transduction efficiency as evaluated using MetaMorpht software package showed 16.6 and 12.3% positive for GFP in mouse and human islets transduced with dsAAV2 as compared to 1.2 and 3.1% with ssAAV2, respectively. We further examined the transduction efficiency of dsAAV2 vectors in INS-1 b-cells 6 days post-transduction. The ssAAV2 vector transduced less than 4% of cells at an MOI of 1000 vg per cell, whereas 63% of the cells were positive for eGFP by flow cytometry when transduced with dsAAV2-eGFP. These results suggest that the dsAAV2 is far more efficient for functional transduction of pancreatic islets compared to ssAAV2.
Gene transfer using a dsAAV2-eGFP vector does not impair viability of mouse islets
To determine whether gene transfer using dsAAV2 vector (10 000 vg per islet cell) was able to maintain islet viability, we used two-color fluorescence assay following staining with Calcein AM and propidium iodide. As shown in Figure 2 , the analysis of extent of viable green cells compared to nonviable red cells revealed that the dsAAV2 gene transfer does not significantly impair islet viability at the two and four day time points posttransduction.
Physiological function is not impaired by dsAAV2-eGFP vector transduction in intact mouse islets in vitro Islets regulate insulin release physiologically in response to glucose, and previous studies have suggested that ssAAV2 transduction of cultured islets does not impair islet function. To determine if transduction of islets with the dsAAV2 vector (10 000 vg per islet cell) maintains normal regulated insulin secretion, an essential requirement for any gene transfer strategy to islets, glucose stimulated insulin secretion of transduced islets was performed using a perifusion protocol. In total, 40 IEQ (islet equivalent) were subjected to low (2.8 mM), high (20 mM) and finally low (2.8 mM) glucose concentrations sequentially in islets at 2 and 4 days post-transduction. As shown in Figure 3 , the basal rate of insulin release in modified islets in low glucose was 0.7 and 0.6 ng/ml/ min, which increased to 14 and 9 ng/ml/min with high glucose on 2 and 4 days post-transduction, respectively. The level of insulin returned subsequently to the basal level during second incubation in low glucose. Importantly, the insulin secretion profile of dsAAV2-eGFP transduced islets was similar to control mock-transduced islets. We also examined whether the dsAAV2 gene transfer and expression of reporter transgene affects insulin content. The dsAAV2 transduced islets showed 4 ng/ml of insulin on day 2 and 2.4 ng/ml on day 4 posttransduction, which was not significantly different from the control, untransduced islets over the same period of transduction.
Gene transfer of islets with dsAAV2-eGFP expresses the transgene long-term compared to ssAAV2-eGFP To determine the duration of ssAAV2 and dsAAV2 gene expression in vivo following islet transplantation, islet grafts were evaluated for eGFP expression at 1 and 2 weeks, and 6 months post-transplantation (Figure 4a ). Our results revealed higher level of transduction in dsAAV2 transduced islets (10 000 vg per islet cell; B and D) as compared to ssAAV2 (10 000 vg per islet cell; A and C). Moreover, the eGFP expression was persisted for at least 6 months post-transplantation (F), whereas almost no eGFP signal was seen in the ssAAV2 transplants at 6 months post-transplantation (E). Fluorescence microscopic analysis of kidneys bearing dsAAV2-eGFP vector transduced islet grafts 2 weeks post-transplantation showed a higher level of reporter transgene expression compared to ssAAV2-eGFP vector transduced islets grafts after same time point ( Figure 4B ; a, b).
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dsAAV2-eGFP transduced islets reverse diabetes in vivo
The ability to restore normoglycemia by genetically modified islets when transplanted into chemically induced diabetic mice is a key indicator of maintenance of islet cell function. To determine whether b-cell function is impaired by dsAAV2 transduction, we transplanted 300 dsAAV transduced islets under the left renal capsule of STZ induced diabetic mice. As shown in Figure 5A , both the dsAAV2 transduced islet grafts (b) and mock-transduced islets grafts (a) restored normoglycemia within 2 days of transplantation and maintained 460 days of study. Moreover, the function of the transplanted islets was confirmed by uni-nephrectomy of the graft-bearing kidney, which resulted in return to hyperglycemia. Furthermore, we evaluated whether the islet grafts transduced with dsAAV2 clear blood glucose when injected using an intraperitoneal glucose tolerance test (IPGTT) protocol ( Figure 5A ). Recipient mice bearing islet grafts transduced with dsAAV2 cleared glucose within 30 min of administration similar to naïve and mock transduced control transplant mice (c). These results demonstrate that the dsAAV2 transduced grafts are able to normalize and maintain normoglycemia in diabetic recipients as compared to control mock-transduced islets.
Immuno and histochemical analysis of insulin and leukocyte infiltration in islet grafts transduced with dsAAV2-eGFP
To examine whether dsAAV2-eGFP transduction results in the induction of an immune response against the transplanted islets, recipient mice were killed 60 days post-transplant and the grafts were analyzed for insulin by immunohistology and for cellular infiltrate by hematoxilin and eosin (H&E) staining. As shown in the Figure 5B , both the control mock-transduced (a) and dsAAV2 transduced islet grafts (b) showed equally insulin positive cells with intact islet architecture. In addition, samples of islet grafts in control and dsAAV2 transduced groups 60 days post-transplantation stained with H&E revealed no infiltration of mononuclear cells in both groups (c, d). Further, no evidence of vector-mediated tissue damage was seen in any of the groups. Figure 1 eGFP expression in pancreatic islets transduced with ssAAV2-eGFP and dsAAV2-eGFP in vitro. Following AAV2 transduction, the islets were cultured for 1 week at 371C and the eGFP expression was visualized by two-photon laser scanning confocal microscopy. eGFP expression in human and mouse islets is not seen in mock (a, d), but seen in ssAAV2-eGFP (b, e) and dsAAV2-eGFP (c, f) vector transduction. Percent transduction was determined by scoring green fluorescence using the MetaMorpht software package (g). Rodent INS-1 b-insulinoma cells were transduced with ss and dsAAV2 and evaluated by flow cytometry (h). These data are the representative (a-f) and mean7s.e. of three independent experiments in duplicate (g, h). Magnification Â 40. **Po0.001; *Po0.015.
Comparison of gene transfer and expression efficiency of different serotypes of dsAAV-eGFP in human pancreatic islets
The results presented above demonstrate efficient transduction of human and murine islets with dsAAV2 based vectors with subsequent long-term expression following transplantation. Previously, it has been demonstrated that transduction of human and murine islets is substantially higher using ssAAV5 and AAV1, respectively, when compared to AAV2. To study whether the transduction efficiency of islets is serotype and targetspecies dependent, we compared the dsAAV2-eGFP packaged in serotypes 1, 2, 5, 6, 7, and 8 in human islets. As shown in Figure 6a , dsAAV2-eGFP vector packaged in serotypes 2, 6, and 8 all transduced human islets more efficiently than the other serotypes. Furthermore, we have examined the kinetics of eGFP expression following infection with ssAAV2 versus dsAAV2 as well as examined the kinetics of expression for dsAAV2, dsAAV6, and dsAAV8. As shown in Figure 6b , expression of dsAAV2 was observed as early as day 2 whereas expression from ssAAV2 was observed at a low level only at day 7. Furthermore, there was no significant difference in the kinetics of gene expression between dsAAV2 and 6 with similar levels of eGFP expression at each time point. However, the results at day 2 compared to day 3 suggest that kinetics of dsAAV8 may be slightly slower than dsAAV2 or dsAAV8 kinetcs of AAV8 may be slightly slower. Taken together, these results suggest that using a dsAAV based vectors in combination with certain serotypes results in efficient and rapid transduction of human islets.
Discussion
Transplantation of allogeneic pancreatic islets, in theory, is an effective approach to treat type 1 diabetes. 6, 7 However, repeated transplantation of islets is commonly required because of loss of the islet graft due to various reasons including both the allo and autoimmune response. In addition, immunosuppressive drugs have also been implicated in the loss of islet mass and islet dysfunction. Transplantation of islets genetically modified ex vivo with cytoprotective and immunoregulatory genes has been successful in animal models. Adenoviral based vectors efficiently transduce both human and murine islets, and thus have been used as a gene transfer Transduction of pancreatic islets with double-stranded AAV KK Rehman et al vector for transient modification of islets. Mouse islets transiently modified with adenoviral vectors expressing immunomodulatory genes have been effectively used in allo and xenotransplantation. [29] [30] [31] [32] However, the inherent immunogenicity, short-term expression of transgene and toxicity due to viral proteins limits the use of adenoviral vectors clinically. Lentiviral vectors also are able to infect murine and human islets similar to adenoviral vectors. However, in contrast to adenoviral vectors, lentiviral vectors give long-term gene expression. The current limitations of lentiviral vectors are safety concerns and difficulty with production. AAV based vectors have been used as an alternative vehicle for gene transfer to islets. However, although ssAAV vectors transduce both human and murine islets, the extremely high viral genome particles or infectious units (IU) are required for efficient transduction limits the use of AAV. In addition, gene expression from ssAAV based vectors is delayed following transduction due to the slow conversion of the single-stranded genome to ds genome. Transcriptionally inactive ssAAV can be effectively converted to functional templates when coinfected with adenovirus, 23 resulting in acceleration of leading strand synthesis. [26] [27] [28] To ameliorate this deficiency, self-complementary dsAAV vectors have been developed recently that allow for more efficient and rapid gene expression following AAV transduction. 33 In this report, we have demonstrated that intact human and murine islets can be transduced with dsAAV2 effectively at a significantly lower viral genome particles compared to ssAAV2. We demonstrate transgene expression in a significant percentage of cells within human and murine islets with dsAAV2 as compared to ssAAV2 at 10 000 vg particles per islet cell. Furthermore, our results demonstrate that transduction of murine islets with dsAAV2 does not alter islet responsiveness to increasing concentrations of glucose. The transduced islets were also functional following transplant into diabetic mice, showing normal islet morphology and there was no evidence of an immune response to either the viral vector or the GFP protein. Moreover, islets transplanted in STZ treated mice transduced with dsAAV2 showed an increase in eGFP expression with time, suggesting continuous recruitment and conversion of dsAAV2 genomes into transcriptionally active templates for at least 2 weeks post-transplant. Interestingly, expression of GFP was observed for at least 6 months post-transplantation, suggesting that there is either no or a minimal immune response to the dsAAV2-eGFP transduced islets and that the dsAAV2 mediated transgene expression persists for extended periods of time, making dsAAV an excellent candidate for longterm stable, gene transduction into islet cells.
The results of this study demonstrate the feasibility of using dsAAV2 for the genetic engineering of islets, which could provide an ideal strategy for clinical islet transplantation. The major disadvantage of dsAAV vector is the decrease in the size limit of the therapeutic genes that can be packaged, which excludes many potentially useful genes. However, there are a large number of potentially therapeutic genes that are approximately 1.2 kb or smaller such as cytokines, costimulatory molecules, or antiapoptotic genes that can be used therapeutically. For example, it has been shown that adenoviral or lentiviral gene transfer of IL-4 is able to block the autoimmune response to transplanted syngeneic islets. 11 Moreover, transfer of genes encoding inhibitors of costimulation such as CTLA4-Ig and sCD40-Ig significantly enhance allogeneic islet graft survival (Rehman et al, unpublished) , similar to what has been Figure 3 Dynamics of insulin release in response to glucose from dsAAV2-eGFP transduced islets by perifusion protocol. A group of 40 mouse islets, either mock transduced or with dsAAV2, were challenged with low (2.8 mM), high (20 mM), and finally low glucose (2.8 mM). Further, a group of 10 islets were sonicated and assayed for total insulin content. The secreted insulin and insulin content was assayed by ELISA. The insulin release and insulin content in mock and dsAAV2 transduced islets on day 2 (a, c) and day 4 (b, d) post-transduction and culture. These data represent the mean7s.e. of three independent experiments in triplicate (c, d) and representative results of two independent experiments (a, b).
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15,34
The results described in this manuscript were performed using the AAV2 serotype, which has been reported to infect human and murine islets less efficiently than other serotypes such as AAV1 and AAV5. 23, 35 However, our analysis using the dsAAV2 vector packaged in serotypes 1, 2, 5, 6, 7, and 8 demonstrated that serotypes 6 and 8 are as least as efficient as serotype 2 for transduction of human islets. In fact, there was no significant difference between serotypes 2, 6, and 8 transduction and kinetics of gene expression although AAV8 might be slightly slower. The reasons why serotypes 1 and in particular 5 are not as effective as previously reported may be due in part to the fact that the analysis was performed using dsAAV, not a ssAAV vector. The use of serotypes 6 and 8 may also help to avoid the deleterious effects of the immune reaction against AAV-delivered transgene products found particularly strong in autoimmunity susceptible strains of Transduction of pancreatic islets with double-stranded AAV KK Rehman et al mice. 36, 37 However, the efficiency of transduction that we have observed with dsAAV serotype 2 already should be sufficient for many therapeutic applications.
Materials and methods

Animals
All animal experiments were conducted and monitored under protocols reviewed and approved by the Institution Animal Care and use Committee. Mice (BALB/c) were purchased from Jackson Laboratories (Bar Harbor, Maine, USA). All animals were housed in the animal facility of University of Pittsburgh and used in compliance with US Department of Agriculture and National Institutes of Health regulations.
Construction and production of AAV vector
AAV vectors were generated by triple plasmid transfection of 293 cells. 38 The adenovirus helper plasmid XX6, 29 and the vector plasmid dsAAV-CB-GFP containing a GFP gene driven by the CB promoter, 33 were the same for the production of all serotype vectors. The pseodotyped AAV packaging plasmids, however, contained each individual serotype capsid gene and coupled with an uniform AAV2 rep gene. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] The resulting AAV serotype viral particles containing the identical AAV vector DNA cassette of GFP gene, packaged by specific serotype capsids for AAV1, AAV2, AAV5, AAV6, AAV7, and AAV8. The different AAV viruses were purified twice with CsCl gradient ultracentrifugation 42 and the titers of vector-genome (vg) particles were determined by a standard dot-blot assay. 42 Islet isolation, transduction, and culture Islets were isolated from the mouse pancreas by intraductal collagenase digestion (Type IX, 1.75 mg/ml, Sigma Chemical Co., St Louis, MO, USA) as described. 29, 43 The isolated islets were further purified by Ficoll density gradient centrifugation and were hand Intraperitoneal glucose tolerance test (IPGTT) was performed in recipient mice before nephrectomy by injecting glucose at a concentration of 2 g/kg bw. Blood glucose was monitored by snipping the tail vein periodically up to 120 min as indicated (C). The blood glucose clearance rate in dsAAV2 transduced islet transplant mice (n ¼ 4) was similar to the naïve controls (n ¼ 4) and mock transduced islet transplants (n ¼ 3). (B) Immuno-and histochemical analysis of insulin and infiltrating leukocytes in islet allografts. Photomicrographs show insulin in mouse islet grafts after dsAAV2-eGFP mediated gene transfer. After 60 days post-transplantation, the recipient mice were killed and the grafts were analyzed by immunohistology for insulin. The dsAAV2 transduced islet grafts (B) and control mock-transduced islet grafts (A) showed comparable insulin production. Histochemical analysis of an islet graft from a recipient mouse stained with H&E for infiltrating leukocytes after 60 days, post-transplantation. Infiltrating mononuclear cells are absent in both mock transduced (C) and dsAAV2 transduced grafts (D). Insets showing whole-islet grafts are at Â 10 magnification. The data are representative of four mice in each group. Magnification Â 40.
Transduction of pancreatic islets with double-stranded AAV KK Rehman et al picked under stereomicroscope. Purity of the islets was determined by Dithizone staining, and was 495% in all isolations. Human islets were obtained from the islet isolation core of the University of Pittsburgh. Cadaveric donor pancreata were subjected to digestion, isolation, and purification as described. 44 Islets of approximately 150 mM in diameter determined by standard algorithm were expressed as islet equivalent (IEQ) and an estimate of 2000 islet cells per IEQ was used for all transduction calculations. For transduction of mouse and human islets, a group of 100-300 IEQ were handpicked, incubated with 10 000 vg per islet cell (in all experiments unless specified) with the different serotypes of dsAAVeGFP for 48 h in RPMI-1640 and CMRL 1066, respectively, supplemented with 20 mM L-glutamine, 100 mg/ ml streptomycin, 100 U/ml penicillin and 10% heatinactivated fetal bovine serum in a humidified 5% CO 2 incubator at 371C. Islet pictures were captured by a twophoton confocal microscope and percent transduction was analyzed using MetaMorpht software package version 6.2 (Universal Imaging Corp., Downingtown, PA, USA). Percentage of transduction was determined by scoring green fluorescence in at least 15-25 islet cell aggregates.
INS-1 b-cells were transduced at a 1000 vg per cell with ss and, dsAAV2-eGFP and were maintained in RPMI-1640 in a humidified 5% CO 2 incubator at 371C. At 1 week after transduction, the cells were analyzed for GFP by flow cytometry.
Determination of islet viability by simultaneous staining of live and dead cells using a two-color fluorescence assay
Cell viability was determined using Calcein AM and propidium iodide. Viable cells convert Calcein AM into green fluorescent products and dead cells incorporate Propidium Iodide into the nucleus, resulting in red fluorescence. 45 A working phosphate buffer solution containing 1 mg/ml Calcein AM and 10 mg/ml of propidium iodide was freshly prepared according to the manufacturer guidelines (Calcein Am and Propidium Iodide, Molecular Probes Inc., Eugene, OR, USA). Islets were incubated in the presence of the dyes for 30 min at 371C prior to evaluation under a fluorescence microscope (Nikon Inc., NY, USA). The percentage of viable cell aggregates was determined by detection of green versus red fluorescence in at least 15-25 IEQ using MetaMorpht software package as described. 43 Evaluation of islets transduced with dsAAV2-eGFP vector by dynamic insulin release using a perifusion protocol Kinetics of insulin release in vitro was studied using the perifusion procedure. The perifusion apparatus consisted of a poly-prep column (Bio-Rad Hercules CA, USA) loaded with pre-swollen Bio-gel (P-2, 200-400 wet mesh (Bio-Rad, Hercules, CA, USA). To minimize the variability of the mean insulin responses, we selected islets with diameters between 100 and 150 mm. For the perifusion, groups of 40 IEQ were handpicked, washed in Krebs-Ringer bicarbonate buffers (pH 7.35) containing 10 mM HEPES, 0.5% bovine serum albumin (Sigma, St Louis, MO, USA), and 2.8 mM glucose. The islets were then gently layered in a poly-prep column that had been pre-loaded with Biogel and maintained at 371C. The column with the islets was gently immersed in the vertical position in the water bath at 371C and the perifusion medium was pumped through the column at a final rate of 1 ml/min using a peristaltic pump. 44 After a 30-min equilibration with Krebs-Ringer bicarbonate buffer containing 2.8 mM glucose, elution fractions of 1 ml/min were collected, first during the 30-min perifusion at 2.8 mM glucose, then during the 30-min perifusion at 20 mM glucose, followed by a 30-min perifusion at 2.8 mM. The perifusion fluid was collected at 1 min intervals using a fraction collector. 45 Samples were kept at low temperature (41C) until the end of the experiment, and they were finally stored at À201C until assayed for insulin. Mouse ELISA Assay (ALPCO, Windham NH, USA) was used to measure insulin concentrations of the elution samples.
Streptozotocin (STZ) treatment
BALB/c mice to be used as transplant recipients were rendered diabetic by a single intraperitoneal (i.p.) injection of STZ (200 mg/kg body weight; SigmaAldrich, St Louis, MO, USA) freshly dissolved in citrate buffer (pH 4.0). 46 The animals were monitored for the onset of diabetes by blood glucose readings from the tail vein 48 h after injection and 2-3 times a week thereafter. Only mice in which blood glucose reached 4300 mg/dl (Precision QID; Medisense, Coleshill, UK) were considered overtly diabetic and used for transplantation and further study.
Syngeneic islet transplantation and graft recovery
Single-stranded AAV2-eGFP or dsAAV2-eGFP transduced islets isolated from BLAB/c mice were transplanted into STZ induced diabetic BALB/c animals. Under sterile conditions, the recipient BALB/c animal was anesthetized by intraperitoneal injection of a 2.5% solution of avertin (0.015-0.017 ml/g body wt). 47 The kidney was exposed and externalized through a small incision in the flank. A small tear was made at one pole of the capsule surrounding the kidney, and the 300 IEQ (islet equivalents) were carefully dispensed into the subcapsular space through the tubing connected to a 1 ml syringe. The kidney was replaced in the abdominal cavity, and the incision was sutured. Successful Transduction of pancreatic islets with double-stranded AAV KK Rehman et al engraftment was defined by reduction of glycemic levels to o200 mg/dl after transplantation. After 60 days posttransplantation, some of the normoglycemic recipients underwent nephrectomy to remove the islet graft. Return to hyperglycemia was interpreted as indirect proof of islet graft function.
Intraperitoneal glucose tolerance test (IPGTT)
IPGTT was performed before nephrectomy in dsAAV2 transduced islet transplanted mice with age-matched normal mice. 48 Before the test the animals were fasted for 4 h followed by an i.p. administration of glucose (2 g/kg body weight). Blood glucose levels were determined in tail blood samples at 0 (prior to glucose administration), 15, 30, 60, and 120 min after glucose administration.
Histological analysis
Paraffin sections (5 mm) were cut from graft-bearing kidneys of treated animals. Tissue sections were stained with mouse insulin antibodies (diluted 1:150; DAKO, Carpinteria, CA, USA) followed by a biotinylated secondary antibody (30 min) and labeled streptavidin (30 min). Chromogen substrate 3,3 0 -diaminobenzidine (Sigma, St Louis, MO, USA) was added for 10 min for enzymatic stain development.
Statistical analysis
All data collected were expressed as mean7s.e.m. and statistics were performed using the SPSS package, and a P-value of less than 0.05 by ANOVA was used to indicate statistically significant differences.
